Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors - Top-Institutions - MDSpire

Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors

  • By

  • Ruiju He

  • Yingting Wei

  • Jing Niu

  • Jinghua Huang

  • Ruolan Wu

  • Kaiyan Gu

  • Anyue Wu

  • Lihua Qiu

  • June 19, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Translational Breast Cancer Research Consortium
    Translational Breast Cancer Research Consortium

    N/A, N/A

    Key Differentiators

    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #4

    Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical Center

    Boston, MA

    Key Differentiators

    • Oncology

  • #5

    Royal Marsden Hospital
    Royal Marsden Hospital

    London, N/A

    Key Differentiators

    • Oncology

Original Source(s)

Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors

  • by Ruiju He, Yingting Wei, Jing Niu, Jinghua Huang, Ruolan Wu, Kaiyan Gu, Anyue Wu, Lihua Qiu

  • June 19, 2026

Related Content

Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma

Neural regulation of tumor progression: implications for hepatocellular carcinoma

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study